<code id='78A994EDE9'></code><style id='78A994EDE9'></style>
    • <acronym id='78A994EDE9'></acronym>
      <center id='78A994EDE9'><center id='78A994EDE9'><tfoot id='78A994EDE9'></tfoot></center><abbr id='78A994EDE9'><dir id='78A994EDE9'><tfoot id='78A994EDE9'></tfoot><noframes id='78A994EDE9'>

    • <optgroup id='78A994EDE9'><strike id='78A994EDE9'><sup id='78A994EDE9'></sup></strike><code id='78A994EDE9'></code></optgroup>
        1. <b id='78A994EDE9'><label id='78A994EDE9'><select id='78A994EDE9'><dt id='78A994EDE9'><span id='78A994EDE9'></span></dt></select></label></b><u id='78A994EDE9'></u>
          <i id='78A994EDE9'><strike id='78A994EDE9'><tt id='78A994EDE9'><pre id='78A994EDE9'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:98
          AI skin cancer detector, dermasensor. -- health tech coverage from STAT
          Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but it’s also not that deadly when caught early. Courtesy DermaSensor

          The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday, giving primary care physicians a new way to evaluate troubling skin spots.

          Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but most types are not that deadly when caught early.

          advertisement

          The device, developed by a small company called DermaSensor, is handheld and uses light to examine suspicious moles on a cellular level. It will be marketed specifically for primary care physicians to use in routine check-ups in patients aged 40 and above.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more
          FDA's Woodcock to retire early next year
          FDA's Woodcock to retire early next year

          PrincipalDeputyFDACommissionerJanetWoodcockStefaniReynolds/TheNewYorkTimesviaAPWASHINGTON—PrincipalD

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Readout Newsletter: Bayer study halts, Carmot to IPO, and more

          KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi